Clinical trials: Head or Neck Cancer
Carcinoma, Squamous Cell of Head and Neck
CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer
The aim of the study is to evaluate the efficacy of CetuGEX™ for the treatment of patients with stage III/IV recurrent and/or metastatic SCCHN as compared to cetuximab (both in combination with platinum-based chemotherapy) in…
- Trial name
- RESGEX (NCT02052960)
- Testing
- CetuGEX™, Cetuximab, Chemotherapy
- Where
- 34 sites in Belgium, France and 5 more
- Volunteers
- 240 people
- Sponsor
- Glycotope GmbH
Squamous Cell Carcinoma of the Head and Neck
Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of palbociclib (Ibrance) plus carboplatin in patients with metastatic head and…
- Trial name
- NCT03194373
- Testing
- Palbociclib, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Michigan Rogel Cancer Center
Squamous Cell Carcinoma of Head and Neck
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab…
- Trial name
- OrigAMI-4 (NCT06385080)
- Testing
- Amivantamab, Pembrolizumab, Paclitaxel
- Where
- 56 sites in United States, China and 9 more
- Volunteers
- 287 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Head and Neck Neoplasms
Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer
This is a Phase II trial evaluating the efficacy and the biological activity of BAY 43-9006 in patients with recurrent and/or metastatic head and neck cancer.
- Trial name
- NCT00199160
- Testing
- BAY 43-9006
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Jules Bordet Institute
Squamous Cell Carcinoma of the Head and Neck
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of…
- Trial name
- KESTREL (NCT02551159)
- Testing
- MEDI4736, Tremelimumab, MEDI4736+Tremelimumab
- Where
- 197 sites in United States, Austria and 21 more
- Volunteers
- 823 people
- Sponsor
- AstraZeneca
Head and Neck Cancer, Radiotherapy by Tomotherapy Exclusive
Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract
This is a study whose main objective is to evaluate prospectively the proportion of patients with severe xerostomia one year after treatment with tomotherapy for head and neck cancer.
- Conditions
- Head and Neck Cancer, Radiotherapy by Tomotherapy Exclusive, With or Without Concurrent Chemotherapy
- Trial name
- TOQUAL (NCT01548846)
- Testing
- Tomotherapy
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Centre Francois Baclesse
Esophageal Cancer
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery.
- Trial name
- NCT03731442
- Testing
- Involved field irradiation, Elective field irradiation, Paclitaxel
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Squamous Cell Carcinoma
A Phase II Trial of PF-00299804 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
Esophageal cancer (EC) is the eighth most common cause of cancer-related death in the worldwide. Systemic chemotherapy in patients with metastatic EC has limited effectiveness, resulting in a median survival of 8 months to…
- Trial name
- NCT01608022
- Testing
- PF804
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Yonsei University
Oral Cavity Neoplasm, Oropharyngeal Neoplasm
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
This randomized phase IIb trial studies how well ACTOplus met extended release (XR) works in treating in patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive treatment.
- Conditions
- Oral Cavity Neoplasm, Oropharyngeal Neoplasm, Stage 0 Oral Cavity Squamous Cell Carcinoma American Joint Committee on Cancer (AJCC) v6 and v7, Stage 0 Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7
- Trial name
- NCT02917629
- Testing
- Laboratory Biomarker Analysis, Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet, Pharmacological Study
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Nasopharyngeal Cancer
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
The study is to evaluate the antiemetic effect of adding fosaprepitant to biplet regimen of tropisetron and dexamethasone for patients with cervical cancer or nasopharyngeal cancer treated with radiotherapy and concomitant weekly…
- Conditions
- Cervical Cancer, Nasopharyngeal Cancer, Chemotherapy-induced Nausea and Vomiting, Radiation-Induced Nausea and Vomiting
- Trial name
- NCT05564286
- Testing
- Fosaprepitant, tropisetron, Dexamethasone
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shantou University Medical College
Part 1, MELANOMA
A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors
Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in previously treated adult patients with…
- Conditions
- Part 1, MELANOMA, SCCHN, OVCA
- Trial name
- NCT02573259
- Testing
- PF-06801591
- Where
- 67 sites in United States, Bulgaria and 5 more
- Volunteers
- 147 people
- Sponsor
- Pfizer
Nasopharyngeal Carcinoma
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent…
- Trial name
- DIAMOND (NCT04907370)
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2)
- Where
- 12 sites in China
- Volunteers
- 532 people
- Sponsor
- Sun Yat-sen University
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving capecitabine after surgery may kill any remaining tumor cells.
- Conditions
- Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx
- Trial name
- NCT00095641
- Testing
- capecitabine, adjuvant therapy, chemotherapy
- Sponsor
- SWOG Cancer Research Network
Cancer-related Problem/Condition, Head and Neck Cancer
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
RATIONALE: Glutamine may be effective in decreasing side effects, such as inflammation of the mouth and throat, caused by radiation therapy. The effectiveness of glutamine for mucositis is not yet known.
- Conditions
- Cancer-related Problem/Condition, Head and Neck Cancer, Pain
- Trial name
- NCT00006994
- Testing
- glutamine, radiation therapy
- Where
- 107 sites in United States, Canada
- Volunteers
- 23 people
- Sponsor
- SWOG Cancer Research Network
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A multicenter, single-arm, first-in-human study to investigate the safety, pharmacokinetics, and preliminary antitumor activity of PLX-61639 in participants with locally advanced or metastatic, relapsed/refractory…
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- NCT07284186
- Testing
- PLX-61639
- Where
- 10 sites in United States
- Volunteers
- 155 people
- Sponsor
- Plexium, Inc.
Colorectal Cancer, Triple Negative Breast Cancer
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma
- Trial name
- NCT04107142
- Testing
- Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Solid Tumor, Head and Neck Cancer
Ixovex-1 Single Agent and Combination Therapy
This is an open-label, dose de-escalating, non-randomised, multi-centre phase I/II study to determine safety and efficacy of the oncolytic virus, Ixovex-1 administered by intratumoural (IT) injection.
- Trial name
- IXACT (NCT06549946)
- Testing
- Ixovex-1, Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Psivac Ltd
Esophageal Squamous Cell Carcinoma
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma are recruited to this prospective non-randomized study comprising two separate cohorts.
- Trial name
- NCT03603756
- Testing
- SHR-1210, Apatinib, Irinotecan Injection
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.